Novo Nordisk seeks to block Sanofi-Aventis insulin pen

07/17/2007 | MSNBC

The Danish drug group says Sanofi-Aventis' Solo-Star injection pen, which delivers Lantus insulin, infringes on Novo Nordisk's NovoPen 4. Competition is heating up over newer-generation versions of human insulin and the technologies for their injectable delivery. Sanofi says it disagrees with Novo Nordisk's claims and plans to "vigorously defend" its rights.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN